Chronic maternal diseases and pregnancy losses. French guidelines;Pathologies maternelles chroniques et pertes de grossesse. Recommandations françaises

Journal de Gynecologie Obstetrique et Biologie de la Reproduction

Volumn 43, Issue 10, 2014, Pages 865-882

  Nizard, J ^a,b   Guettrot Imbert, G ^c   Plu Bureau, G ^d   Ciangura, C ^a   Jacqueminet, S ^a   Leenhardt, L ^a   Nedellec, S ^e   Gallot, V ^e   Vialard, F ^f,g   Quibel, T ^f   Huchon, C ^f,h   Costedoat Chalumeau, N ^h  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b INSERM   (France)

^c SERVICE DE RHUMATOLOGIE   (France)

^d Maternité Port Royal ^*  (France)

^e HÔPITAL ANTOINE BÉCLÈRE   (France)

^f CENTRE HOSPITALIER INTERCOMMUNAL   (France)

^g INRA Institut National de la Recherche Agronomique   (France)

^h Risques Cliniques et Securite en Sante des Femmes et en Sante Perinatale   (France)

Author keywords

Antiphospholipidsyndrome; Chronic maternaldisease; Diabetes; Miscarriage; Obesity; Pregnancy loss; Stillbirth; Thrombophilias

Indexed keywords

ANTIBODY; BETA 2 GLYCOPROTEIN ANTIBODY; CARDIOLIPIN ANTIBODY; HEMOGLOBIN A1C; LEVOTHYROXINE; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; CHRONIC DISEASE; FOLLOW UP; GLYCEMIC CONTROL; HUMAN; HYPOTHYROIDISM; MATERNAL DISEASE; PRACTICE GUIDELINE; PREGNANCY DIABETES MELLITUS; PREGNANCY DISORDER; PREGNANCY LOSS; SPONTANEOUS ABORTION; ABORTION, SPONTANEOUS; FEMALE; FETUS DEATH; FRANCE; PREGNANCY; PREGNANCY COMPLICATIONS; PREVENTION AND CONTROL; STANDARDS;

ABORTION, SPONTANEOUS; CHRONIC DISEASE; FEMALE; FETAL DEATH; FRANCE; HUMANS; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 84920175671     PISSN: 03682315     EISSN: 17730430     Source Type: Journal    
DOI: None     Document Type: Article

References (101)

1. Cervera R, Doria A, Amoura Z, Khamashta M, Schneider M, Guillemin F, et al. Patterns of systemic lupus erythematosusexpression in Europe. Autoimmun Rev 2014; 13: 621-9.
2. Clowse ME, Magder LS, Petri M. The clinical utility of measu-ring complement and anti-dsDNA antibodies during pregnancyin patients with systemic lupus erythematosus. J Rheumatol2011; 38: 1012-6.
3. Clowse ME, Magder LS, Witter F, Petri M. The impact of increa-sed lupus activity on obstetric outcomes. Arthritis Rheum2005; 52: 514-21.
4. Clowse ME, Magder LS, Witter F, Petri M. Early risk factors forpregnancy loss in lupus. Obstet Gynecol 2006; 107: 293-9.
5. Al Arfaj AS, Khalil N. Pregnancy outcome in 396 pregnanciesin patients with SLE in Saudi Arabia. Lupus 2010; 19: 1665-73.
6. Hamed HO, Ahmed SR, Alzolibani A, Kamal MM, MostafaMS, Gamal RM, et al. Does cutaneous lupus erythemato-sus have more favorable pregnancy outcomes than systemicdisease? A two-center study. Acta Obstet Gynecol Scand2013; 92: 934-42.
7. Ko HS, Ahn HY, Jang DG, Choi SK, Park YG, Park IY, et al. Pregnancy outcomes and appropriate timing of pregnancy in183 pregnancies in Korean patients with SLE. Int J Med Sci2011; 8: 577-83.
8. Le Thi Huong D, Wechsler B, Vauthier-Brouzes D, Duhaut P, Costedoat N, Andreu MR, et al. The second trimesterDoppler ultrasound examination is the best predictor oflate pregnancy outcome in systemic lupus erythemato-sus and/or the antiphospholipid syndrome. Rheumatology(Oxford) 2006; 45: 332-8.
9. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on anupdate of the classification criteria for definite antiphospho-lipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
10. Petri M. Prospective study of systemic lupus erythematosuspregnancies. Lupus 2004; 13: 688-9.
11. Gladman DD, Tandon A, Ibanez D, Urowitz MB. The effect oflupus nephritis on pregnancy outcome and fetal and maternalcomplications. J Rheumatol 2010; 37: 754-8.
12. Dhar JP, Essenmacher LM, Ager JW, Sokol RJ. Pregnancyoutcomes before and after a diagnosis of systemic lupus ery-thematosus. Am J Obstet Gynecol 2005; 193: 1444-55.
13. Shand AW, Algert CS, March L, Roberts CL. Second pregnancyoutcomes for women with systemic lupus erythematosus. AnnRheum Dis 2013; 72: 547-51.
14. Cortes-Hernandez J, Ordi-Ros J, Paredes F, Casellas M, Castillo F, Vilardell-Tarres M. Clinical predictors of fetal andmaternal outcome in systemic lupus erythematosus: a pros-pective study of 103 pregnancies. Rheumatology (Oxford)2002; 41: 643-50.
15. Madazli R, Yuksel MA, Oncul M, Imamoglu M, Yilmaz H. Obs-tetric outcomes and prognostic factors of lupus pregnancies. Arch Gynecol Obstet 2014; 289: 49-53.
16. Smyth A, Oliveira GH, Lahr BD, Bailey KR, Norby SM, Garovic VD. A systematic review and meta-analysis ofpregnancy outcomes in patients with systemic lupus erythe-matosus and lupus nephritis. Clin J Am Soc Nephrol 2010; 5: 2060-8.
17. Moroni G, Quaglini S, Banfi G, Caloni M, Finazzi S, Ambroso G, et al. Pregnancy in lupus nephritis. Am J Kidney Dis2002; 40: 713-20.
18. Molad Y, Borkowski T, Monselise A, Ben-Haroush A, Sulkes J, Hod M, et al. Maternal and fetal outcome of lupus pre-gnancy: a prospective study of 29 pregnancies. Lupus2005; 14: 145-51.
19. Georgiou PE, Politi EN, Katsimbri P, Sakka V, Drosos AA. Out-come of lupus pregnancy: a controlled study. Rheumatology(Oxford) 2000; 39: 1014-9.
20. Imbasciati E, Tincani A, Gregorini G, Doria A, Moroni G, Cabiddu G, et al. Pregnancy in women with pre-existing lupusnephritis: predictors of fetal and maternal outcome. NephrolDial Transplant 2009; 24: 519-25.
21. Andrade R, Sanchez ML, Alarcon GS, Fessler BJ, Fernandez M, Bertoli AM, et al. Adverse pregnancyoutcomes in women with systemic lupus erythematosus froma multiethnic US cohort: LUMINA (LVI) [corrected]. Clin ExpRheumatol 2008; 26: 268-74.
22. Kwok LW, Tam LS, Zhu T, Leung YY, Li E. Predictors of maternaland fetal outcomes in pregnancies of patients with systemiclupus erythematosus. Lupus 2011; 20: 829-36.
23. Levy RA, Vilela VS, Cataldo MJ, Ramos RC, Duarte JL, Tura BR, et al. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus 2001; 10: 401-4.
24. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on pre-liminary classification criteria for definite antiphospholipidsyndrome: report of an international workshop. ArthritisRheum 1999; 42: 1309-11.
25. Gallot V, Nedellec S, Capmas P, Legendre G, Lejeune-Saada V, Subtil D, et al. Fausses couches précoces à répétition : bilan et prise en charge. J Gynecol Obstet Biol Reprod 2014, http://dx.doi.org/10.1016/j.jgyn.2014.09.014.
26. Ruffatti A, Tonello M, Visentin MS, Bontadi A, Hoxha A, DeCarolis S, et al. Risk factors for pregnancy failure in patientswith antiphospholipid syndrome treated with conventionaltherapies: a multicentre, case-control study. Rheumatology(Oxford) 2011; 50: 1684-9.
27. Lockshin MD, Kim M, Laskin CA, Guerra M, Branch DW, Merrill J, et al. Prediction of adverse pregnancy outcomeby the presence of lupus anticoagulant, but not anticardio-lipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum 2012; 64: 2311-8.
28. Empson M, Lassere M, Craig J, Scott J. Prevention ofrecurrent miscarriage for women with antiphospholipid anti-body or lupus anticoagulant. Cochrane Database Syst Rev2005: CD002859.
29. Fouda UM, Sayed AM, Abdou AM, Ramadan DI, Fouda IM, Zaki MM. Enoxaparin versus unfractionated heparin inthe management of recurrent abortion secondary to anti-phospholipid syndrome. Int J Gynaecol Obstet 2011; 112: 211-5.
30. Noble LS, Kutteh WH, Lashey N, Franklin RD, Herrada J. Anti-phospholipid antibodies associated with recurrent pregnancyloss: prospective, multicenter, controlled pilot study com-paring treatment with low-molecular-weight heparin versusunfractionated heparin. Fertil Steril 2005; 83: 684-90.
31. Stephenson MD, Ballem PJ, Tsang P, Purkiss S, Ensworth S, Houlihan E, et al. Treatment of antiphospholipid antibody syn-drome (APS) in pregnancy: a randomized pilot trial comparinglow-molecular-weight heparin to unfractionated heparin. JObstet Gynaecol Can 2004; 26: 729-34.
32. http://www.afssaps.fr/Infos-de-securite/Recommandations-de-bonne-pratique/Prevention-et-traitement-de-la-maladie-thromboembolique-veineuse-en-medecine-recommandations-de-bonne-pratique. Novembre 2009.
33. Carlin AJ, Farquharson RG, Quenby SM, Topping J, Fraser WD. Prospective observational study of bone mineral den-sity during pregnancy: low-molecular-weight heparin versuscontrol. Hum Reprod 2004; 19: 1211-4.
34. Mak A, Cheung MW, Cheak AA, Ho RC. Combination of hepa-rin and aspirin is superior to aspirin alone in enhancing livebirths in patients with recurrent pregnancy loss and positiveantiphospholipid antibodies: a meta-analysis of randomizedcontrolled trials and meta-regression. Rheumatology (Oxford)2010; 49: 281-8.
35. Bouvier S, Cochery-Nouvellon E, Lavigne-Lissalde G, Mercier E, Fabbro-Peray P, Balducchi JP, et al. Comparativeincidence of pregnancy outcomes in thrombophilia-positivewomen from the NOH-APS observational study. Blood2014; 123: 414-21.
36. Rand JH, Wu XX, Quinn AS, Ashton AW, Chen PP, Hath-cock JJ, et al. Hydroxychloroquine protects the annexin A5anticoagulant shield from disruption by antiphospholipid anti-bodies: evidence for a novel effect for an old antimalarialdrug. Blood 2010; 115: 2292-9.
37. Albert CR, Schlesinger WJ, Viall CA, Mulla MJ, Brosens JJ, Chamley LW, et al. Effect of hydroxychloroquine on anti-phospholipid antibody-induced changes in first trimestertrophoblast function. Am J Reprod Immunol 2014; 71: 154-64.
38. Marchetti T, Ruffatti A, Wuillemin C, de Moerloose P, CohenM. Hydroxychloroquine restores trophoblast fusion affec-ted by antiphospholipid antibodies. J Thromb Haemost2014; 12: 910-20.
39. Bramham K, Thomas M, Nelson-Piercy C, Khamashta M, Hunt BJ. First trimester low-dose prednisolone in refrac-tory antiphospholipid antibody-related pregnancy loss. Blood2011; 117: 6948-51.
40. Dudding TE, Attia J. Maternal factor V Leiden and adversepregnancy outcome: deciding whether or not to test. J MaternFetal Neonatal Med 2012; 25: 889-94.
41. Robertson L, Wu O, Langhorne P, Twaddle S, Clark P, Lowe GD, et al. Thrombophilia in pregnancy: a systematic review. Br JHaematol 2006; 132: 171-96.
42. Rodger MA, Betancourt MT, Clark P, Lindqvist PG, Dizon-Townson D, Said J, et al. The association of factor V Leidenand prothrombin gene mutation and placenta-mediated pre-gnancy complications: a systematic review and meta-analysisof prospective cohort studies. PLoS Med 2010; 7: e1000292.
43. Lissalde-Lavigne G, Fabbro-Peray P, Cochery-Nouvellon E, Mercier E, Ripart-Neveu S, Balducchi JP, et al. Factor VLeiden and prothrombin G20210A polymorphisms as risk fac-tors for miscarriage during a first intended pregnancy: thematched case-control 'NOHA first' study. J Thromb Haemost2005; 3: 2178-84.
44. Rey E, Kahn SR, David M, Shrier I. Thrombophilic disorders andfetal loss: a meta-analysis. Lancet 2003; 361: 901-8.
45. Bennett SA, Bagot CN, Arya R. Pregnancy loss and thrombo-philia: the elusive link. Br J Haematol 2012; 157: 529-42.
46. Brenner B, Hoffman R, Carp H, Dulitsky M, Younis J, Investi-Gators L-E. Efficacy and safety of two doses of enoxaparin inwomen with thrombophilia and recurrent pregnancy loss: theLIVE-ENOX study. J Thromb Haemost 2005; 3: 227-9.
47. Gris JC, Mercier E, Quere I, Lavigne-Lissalde G, Cochery-Nouvellon E, Hoffet M, et al. Low-molecular-weightheparin versus low-dose aspirin in women with one fetalloss and a constitutional thrombophilic disorder. Blood2004; 103: 3695-9.
48. Rodger MA, Hague WM, Kingdom J, Kahn SR, Karo-Vitch A, Sermer M, et al. Antepartum dalteparin versusno antepartum dalteparin for the prevention of pre-gnancy complications in pregnant women with thrombophilia(TIPPS): a multinational open-label randomised trial. Lan-cet 2014, http://dx.doi.org/10.1016/S0140-6736(14)60793-5[sous presse].
49. Siu SC, Sermer M, Harrison DA, Grigoriadis E, Liu G, Soren-Sen S, et al. Risk and predictors for pregnancy-relatedcomplications in women with heart disease. Circulation1997; 96: 2789-94.
50. Siu SC, Colman JM, Sorensen S, Smallhorn JF, Farine D, Amank-Wah KS, et al. Adverse neonatal and cardiac outcomes aremore common in pregnant women with cardiac disease. Cir-culation 2002; 105: 2179-84.
51. McLintock C, McCowan LM, North RA. Maternal complicationsand pregnancy outcome in women with mechani-cal prosthetic heart valves treated with enoxaparin. BJOG 2009; 116: 1585-92, http://dx.doi.org/10.1111/j.1471-0528.2009.02299.x.
52. Basude S, Hein C, Curtis SL, Clark A, Trinder J. Low-molecular-weight heparin or warfarin for anticoagulation in pregnantwomen with mechanical heart valves: what are the risks? Aretrospective observational study. BJOG 2012; 119: 1008-13, http://dx.doi.org/10.1111/j.1471-0528.2012.03359.x[discussion 12-3].
53. Chen CH, Huang MC, Liu HC, Huang CJ, Lin HC, Kou YR. Increased risk of preterm birth among women withmitral valve prolapse: a nationwide, population-basedstudy. Ann Epidemiol 2011; 21: 391-8, http://dx.doi.org/10.1016/j.annepidem.2011.02.004.
54. Lerman TT, Weintraub AY, Sheiner E. Pregnancy out-comes in women with mitral valve prolapse and mitralvalve regurgitation. Arch Gynecol Obstet 2013; 288: 287-91, http://dx.doi.org/10.1007/s00404-013-2755-6.
55. Drenthen W, Pieper PG, Roos-Hesselink JW, van Lot-Tum WA, Voors AA, Mulder BJ, et al. Outcome ofpregnancy in women with congenital heart disease: aliterature review. J Am Coll Cardiol 2007; 49: 2303-11, http://dx.doi.org/10.1016/j.jacc.2007.03.027.
56. Aune D, Saugstad OD, Henriksen T, Tonstad S. Maternal body mass index and the risk of fetaldeath, stillbirth, and infant death: a systematicreview and meta-analysis. JAMA 2014; 311: 1536-46, http://dx.doi.org/10.1001/jama.2014.2269.
57. Yao R, Ananth CV, Park BY, Pereira L, Plante LA, Perinatal Research C. Obesity and the risk of stillbirth: a population-based cohort study. Am J Obstet Gynecol 2014; 210: 457, http://dx.doi.org/10.1016/j.ajog.2014.01.044 [e1-9].
58. Furber CM, McGowan L, Bower P, Kontopantelis E, Quenby S, Lavender T. Antenatal interventions for reducingweight in obese women for improving pregnancy out-come. Cochrane Database Syst Rev 2013; 1: CD009334, http://dx.doi.org/10.1002/14651858.CD009334.pub2.
59. Oteng-Ntim E, Varma R, Croker H, Poston L, Doyle P. Lifestyle interventions for overweight and obese pre-gnant women to improve pregnancy outcome: syste-matic review and meta-analysis. BMC Med 2012; 10: 47, http://dx.doi.org/10.1186/1741-7015-10-47.
60. Villamor E, Cnattingius S. Interpregnancy weightchange and risk of adverse pregnancy outcomes: apopulation-based study. Lancet 2006; 368: 1164-70, http://dx.doi.org/10.1016/S0140-6736(06)69473-7.
61. Haute Autorité de santé (HAS). Surpoids et obésité del'adulte: prise en charge médicale de premier recours. Saint-Denis la Plaine: Haute Autorité de santé; 2011.
62. Berlac JF, Skovlund CW, Lidegaard O. Obstetrical and neonataloutcomes in women following gastric bypass: a Danish natio-nal cohort study. Acta Obstet Gynecol Scand 2014; 93: 447-53, http://dx.doi.org/10.1111/aogs.12368.
63. Roos N, Neovius M, Cnattingius S, Trolle Lagerros Y, Saaf M, Granath F, et al. Perinatal outcomes after bariatric sur-gery: nationwide population-based matched cohort study. BMJ 2013; 347: f6460, http://dx.doi.org/10.1136/bmj.f6460.
64. Scott-Pillai R, Spence D, Cardwell CR, Hunter A, Holmes VA. The impact of body mass index on maternal andneonatal outcomes: a retrospective study in a UK obs-tetric population, 2004-2011. BJOG 2013; 120: 932-9, http://dx.doi.org/10.1111/1471-0528.12193.
65. Khashan AS, Kenny LC. The effects of maternal bodymass index on pregnancy outcome. Eur J Epidemiol2009; 24: 697-705, http://dx.doi.org/10.1007/s10654-009-9375-2.
66. Sebire NJ, Jolly M, Harris J, Regan L, Robinson S. Ismaternal underweight really a risk factor for adverse pre-gnancy outcome? A population-based study in London. BJOG2001; 108: 61-6.
67. Feodor Nilsson S, Andersen P, Strandberg-Larsen K, NyboAndersen AM. Risk factors for miscarriage from a preven-tion perspective: a nationwide follow-up study. BJOG 2014, http://dx.doi.org/10.1111/1471-0528.12694 [sous presse].
68. Maconochie N, Doyle P, Prior S, Simmons R. Risk factors forfirst trimester miscarriage-results from a UK-population-based case-control study. BJOG 2007; 114: 170-86.
69. Lashen H, Fear K, Sturdee DW. Obesity is associated withincreased risk of first trimester and recurrent miscarriage: matched case-control study. Hum Reprod 2004; 19: 1644-6.
70. Baba S, Noda H, Nakayama M, Waguri M, Mitsuda N, Iso H. Risk factors of early spontaneous abortions among Japanese: a matched case-control study. Hum Reprod 2011; 26: 466-72.
71. Maggard MA, Yermilov I, Li Z, Maglione M, Newberry S, Suttorp M, et al. Pregnancy and fertility following bariatric surgery: a systematic review. JAMA 2008; 300: 2286-96.
72. Bismuth E, Bouche C, Caliman C, Lepercq J, Lubin V, Rouge D, et al. Management of pregnancy in women with type 1 dia-betes mellitus: guidelines of the French-Speaking DiabetesSociety (Société francophone du diabète [SFD]). DiabetesMetab 2012; 38: 205-16.
73. Mills JL, Simpson JL, Driscoll SG, Jovanovic-Peterson L, VanAllen M, Aarons JH, et al. Incidence of spontaneous abortionamong normal women and insulin-dependent diabetic womenwhose pregnancies were identified within 21 days of concep-tion. New Engl J Med 1988; 319: 1617-23.
74. Dicker D, Feldberg D, Samuel N, Yeshaya A, Karp M, Goldman JA. Spontaneous abortion in patients with insulin-dependentdiabetes mellitus: the effect of preconceptional diabeticcontrol. Am J Obstet Gynecol 1988; 158: 1161-4.
75. Hanson U, Persson B, Thunell S. Relationship between hae-moglobin A1C in early type 1 (insulin-dependent) diabeticpregnancy and the occurrence of spontaneous abortion andfetal malformation in Sweden. Diabetologia 1990; 33: 100-4.
76. Kitzmiller JL, Buchanan TA, Kjos S, Combs CA, Ratner RE. Pre-conception care of diabetes, congenital malformations, andspontaneous abortions. Diabetes Care 1996; 19: 514-41.
77. Bell R, Bailey K, Cresswell T, Hawthorne G, Critchley J, Lewis-Barned N, et al. Trends in prevalence and outcomesof pregnancy in women with pre-existing type I and type IIdiabetes. BJOG 2008; 115: 445-52.
78. Peticca P, Keely EJ, Walker MC, Yang Q, Bottomley J. Pre-gnancy outcomes in diabetes subtypes: how do they compare?A province-based study of Ontario, 2005-2006. J ObstetGynaecol Can 2009; 31: 487-96.
79. Wood SL, Jick H, Sauve R. The risk of stillbirth in pregnan-cies before and after the onset of diabetes. Diabet Med2003; 20: 703-7.
80. Shand AW, Bell JC, McElduff A, Morris J, Roberts CL. Outcomesof pregnancies in women with pregestational diabetes mel-litus and gestational diabetes mellitus; a population-basedstudy in New South Wales, Australia, 1998-2002. Diabet Med2008; 25: 708-15.
81. Boulot P, Chabbert-Buffet N, d'Ercole C, Floriot M, Fontaine P, Fournier A, et al. French multicentric survey of outcome ofpregnancy in women with pregestational diabetes. DiabetesCare 2003; 26: 2990-3.
82. Confidential Enquiry into Maternal and Child Health. Pre-gnancy in women with type 1 and type 2 diabetes in 2002-03, England, Wales and Northern Ireland. London: CEMACH; 2005.
83. Wahabi HA, Alzeidan RA, Esmaeil SA. Prepregnancy care forwomen with pregestational diabetes mellitus: a systematicreview and meta-analysis. BMC Public Health 2012; 12: 792.
84. Middleton P, Crowther CA, Simmonds L. Different intensitiesof glycaemic control for pregnant women with pre-existingdiabetes. Cochrane Database Syst Rev 2012; 8: CD008540.
85. Secher AL, Ringholm L, Andersen HU, Damm P, Mathiesen ER. The effect of real-time continuous glucose monitoring inpregnant women with diabetes: a randomized controlledtrial. Diabetes Care 2013; 36: 1877-83.
86. Murphy HR, Rayman G, Lewis K, Kelly S, Johal B, Duffield K, et al. Effectiveness of continuous glucose monitoring inpregnant women with diabetes: randomised clinical trial. BMJ2008; 337: a680.
87. American College of Obstetricians and Gynecologists, TaskForce on Hypertension in Pregnancy. Report of the Ame-rican College of Obstetricians and Gynecologists' TaskForce on hypertension in pregnancy. Obstet Gynecol2013; 122: 1122-31.
88. European Society of Gynecology, Association for EuropeanPaediatric Cardiology, German Society for Gender Medi-cine, Authors/Task Force M, Regitz-Zagrosek V, BlomstromLundqvist C, et al. ESC Guidelines on the management ofcardiovascular diseases during pregnancy: the Task Force onthe Management of Cardiovascular Diseases during Pregnancyof the European Society of Cardiology (ESC). Eur Heart J2011; 32: 3147-97.
89. Bramham K, Parnell B, Nelson-Piercy C, Seed PT, Poston L, Chappell LC. Chronic hypertension and pregnancy outcomes: systematic review and meta-analysis. BMJ 2014; 348: g2301.
90. Aagaard-Tillery KM, Holmgren C, Lacoursiere DY, Houssain S, Bloebaum L, Satterfield R, et al. Factors associated with nona-nomalous stillbirths: the Utah Stillbirth Database 1992-2002. Am J Obstet Gynecol 2006; 194: 849-54.
91. Ahmad AS, Samuelsen SO. Hypertensive disorders in pre-gnancy and fetal death at different gestational lengths: a population study of 2, 121, 371 pregnancies. BJOG2012; 119: 1521-8.
92. Yanit KE, Snowden JM, Cheng YW, Caughey AB. The impactof chronic hypertension and pregestational diabetes on pre-gnancy outcomes. Am J Obstet Gynecol 2012; 207: 333 [e1-6].
93. Abalos E, Duley L, Steyn DW. Antihypertensive drug the-rapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev 2014; 2: CD002252.
94. van den Boogaard E, Vissenberg R, Land JA, van Wely M, vander Post JA, Goddijn M, et al. Significance of (sub)clinicalthyroid dysfunction and thyroid autoimmunity before concep-tion and in early pregnancy: a systematic review. Hum ReprodUpdate 2011; 17: 605-19.
95. Stagnaro-Green A, Abalovich M, Alexander E, Azizi F, Mest-man J, Negro R, et al. Guidelines of the American ThyroidAssociation for the diagnosis and management of thy-roid disease during pregnancy and postpartum. Thyroid2011; 21: 1081-125.
96. Abalovich M, Gutierrez S, Alcaraz G, Maccallini G, Garcia A, Levalle O. Overt and subclinical hypothyroidism complicatingpregnancy. Thyroid 2002; 12: 63-8.
97. Allan WC, Haddow JE, Palomaki GE, Williams JR, Mitchell ML, Hermos RJ, et al. Maternal thyroid deficiency and pregnancycomplications: implications for population screening. J MedScreen 2000; 7: 127-30.
98. Negro R, Schwartz A, Gismondi R, Tinelli A, Mangieri T, Stagnaro-Green A. Increased pregnancy loss rate in thyroidantibody negative women with TSH levels between 2.5 and5.0 in the first trimester of pregnancy. J Clin Endocrinol Metab2010; 95: E44-8.
99. Negro R, Formoso G, Mangieri T, Pezzarossa A, Dazzi D, Hassan H. Levothyroxine treatment in euthyroid pregnantwomen with autoimmune thyroid disease: effects on obstetri-cal complications. J Clin Endocrinol Metab 2006; 91: 2587-91.
100. Thangaratinam S, Tan A, Knox E, Kilby MD, Franklyn J, Cooma-rasamy A. Association between thyroid autoantibodies andmiscarriage and preterm birth: meta-analysis of evidence. BMJ 2011; 342: d2616.
101. Casey BM, Leveno KJ. Thyroid disease in pregnancy. ObstetGynecol 2006; 108: 1283-92.